{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:32:33Z","timestamp":1770067953836,"version":"3.49.0"},"reference-count":170,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":5029,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1999,6]]},"abstract":"<jats:p><jats:italic>A review of the drug class of angiotensin receptor blockers (ARBs) as well as the ARBs currently available by prescription in the United States is presented. The importance of angiotensin II production by non\u2010angiotensin\u2010converting enzyme (non\u2010ACE) pathways, particularly human chymase, is discussed. Emphasis is placed on the mechanism of action of ARBs and the different binding kinetics of these agents. Although all ARBs, as a group, block the AT<\/jats:italic><jats:sub>1<\/jats:sub> <jats:italic>receptor, they may differ in the pharmacological characteristics of their binding and be classified as either surmountable or insurmountable antagonists. Mechanisms of surmountable and insurmountable antagonism as well as possible benefits of these blocking characteristics are discussed in relation to the various ARBs. The cardiovascular effects of activation of the two main subtypes of angiotensin receptors (AT<\/jats:italic><jats:sub>1<\/jats:sub> <jats:italic>and AT<\/jats:italic><jats:sub>2<\/jats:sub><jats:italic>) are presented. In addition to their treatment of hypertension, ACE inhibitors are recognized as being effective in the management of heart failure, left ventricular hypertrophy, recurrent myocardial infarctions, and renal disease. ARBs are currently indicated only for the treatment of hypertension; however, in vitro and in vivo pharmacological studies as well as preliminary clinical data suggest that ARBs, like ACE inhibitors, may also provide effective protection against end\u2010organ damage in these conditions<\/jats:italic>.<\/jats:p>","DOI":"10.1177\/00912709922008155","type":"journal-article","created":{"date-parts":[[2003,7,19]],"date-time":"2003-07-19T09:38:13Z","timestamp":1058607493000},"page":"547-559","source":"Crossref","is-referenced-by-count":44,"title":["Practical Considerations of the Pharmacology of Angiotensin Receptor Blockers"],"prefix":"10.1002","volume":"39","author":[{"given":"Mona M.","family":"McConnaughey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Scott","family":"McConnaughey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alphonse J.","family":"Ingenito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"40.1","volume-title":"The Renin\u2010Angiotensin System: Vol 1. Biochemistry\/Physiology","author":"Gavras I","year":"1993"},{"issue":"4","key":"e_1_2_1_3_2","first-page":"684","article-title":"Pilot study of a new angiotensin II receptor antagonist, TCV\u2010116: effects of a single oral dose on blood pressure in patients with essential hypertension","volume":"15","author":"Ogihara T","year":"1993","journal-title":"Clin Ther"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(94)90061-2"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1977.57.2.313"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0889-8529(18)30106-3","article-title":"Essential hypertension as an endocrine disease","volume":"23","author":"Williams GH","year":"1994","journal-title":"Endocrinol Metab Clin North Am"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1997.tb01788.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199109010-00002"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ajh\/5.5.276","article-title":"Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart: mediation by the AT1 receptor","volume":"5","author":"Dostal DE","year":"1992","journal-title":"Am J Hypertens"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.82.11.1145"},{"issue":"11","key":"e_1_2_1_11_2","first-page":"18","article-title":"Vasculoprotective and cardioprotective mechanisms of angiotensin converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide","volume":"20","author":"Gibbins GH","year":"1997","journal-title":"Clin Cardiol"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(87)90013-7"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(92)90008-N"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1998.tb01572.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198211000-00014"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.9.6_Pt_2.III42"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.80.2.219"},{"issue":"1","key":"e_1_2_1_18_2","first-page":"34","article-title":"The unusual substrate specificity and the distribution of human angiotensin I converting enzyme","volume":"8","author":"Erdos EG","year":"1989","journal-title":"Hypertens"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199311000-00001"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641969709083197"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979010"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90026-0"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199404000-00012"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199002000-00015"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.41.4.26"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198406000-00010"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198912000-00001"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)45712-2"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.66.4.883"},{"issue":"12","key":"e_1_2_1_30_2","first-page":"119","article-title":"The renin\u2010angiotensin system and vascular function: the role of angiotensin II, angiotensin converting enzyme, and alternative conversion of angiotensin I","author":"Roks A","year":"1997","journal-title":"Heart Vessels"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.23.6.857"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.62.207"},{"key":"e_1_2_1_33_2","first-page":"13F","article-title":"The chymase\u2010angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases","volume":"11","author":"Liao Y","year":"1995","journal-title":"Can J Cardiol"},{"issue":"4","key":"e_1_2_1_34_2","first-page":"H769","article-title":"Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations","volume":"273","author":"Balcells E","year":"1997","journal-title":"Am J Physiol"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(93)81348-4"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(95)00349-5"},{"key":"e_1_2_1_37_2","first-page":"278","article-title":"Pathogenic role of non\u2010ACE dependent angiotensin II\u2010forming system in neointimal formation (abstract)","volume":"16","author":"Okunishi H","year":"1993","journal-title":"Hypertens Res"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.13.6.706"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.30.3.383"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00388-9"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.1955.sp001097"},{"key":"e_1_2_1_42_2","first-page":"575","article-title":"Angiotensin II receptor binding inhibitors","volume":"17","author":"Hodges JC","year":"1992","journal-title":"Drugs Fut"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb16191.x"},{"key":"e_1_2_1_44_2","first-page":"331","volume-title":"Pharmacologic Analysis of Drug\u2010Receptor Interaction","author":"Kenakin TP","year":"1997"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb14322.x"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(96)00837-0"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-120-30547"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00515556"},{"key":"e_1_2_1_49_2","first-page":"49","article-title":"Non\u2010peptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP753","volume":"258","author":"Wong PC","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(94)90156-2"},{"key":"e_1_2_1_51_2","first-page":"1081","article-title":"Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies","volume":"41","author":"Wienen W","year":"1992","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199715070-00001"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/0160-5402(88)90064-2"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(91)91969-J"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430080120"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1996.tb02817.x"},{"key":"e_1_2_1_57_2","first-page":"753","article-title":"Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism","volume":"273","author":"Panek RL","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"e_1_2_1_58_2","first-page":"S19","article-title":"Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers","volume":"11","author":"Hubner R","year":"1997","journal-title":"J Hum Hypertens"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732010-00001"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(89)91054-1"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(89)92133-5"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606203342507"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(86)90632-6"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.31.5.1171"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.73.3.413"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405193302008"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199707000-00011"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853899708998740"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.23.10663"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.36.040196.001433"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000639"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1995.tb01032.x"},{"key":"e_1_2_1_73_2","first-page":"205","article-title":"Angiotensin II receptors and angiotensin II receptor antagonists","volume":"45","author":"Timmermans PB","year":"1993","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117710"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/377748a0"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.8.3521"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)92657-3"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/3.4.331"},{"issue":"2","key":"e_1_2_1_79_2","first-page":"37","article-title":"Angiotensin converting enzyme inhibitors: properties and side effects","volume":"11","author":"Gavras H","year":"1988","journal-title":"Hypertens"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91547-9"},{"key":"e_1_2_1_81_2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.1988.03410070095035","article-title":"Clinical profile of angioedema associated with angiotensin converting enzyme inhibition","volume":"260","author":"Slater EE","year":"1988","journal-title":"JAMA"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199700545-00005"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/16.suppl_I.87"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199700545-00009"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810293391804"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(97)80086-0"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.3109\/08037059609062128"},{"issue":"19","key":"e_1_2_1_88_2","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1001\/jama.1997.03550190036037","article-title":"Losartan\u2010induced hepatotoxicity","volume":"278","author":"Bosch X","year":"1997","journal-title":"JAMA"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90047-1"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530160018018"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.73.856.105"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199705000-00020"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1006\/dbio.1997.8764"},{"issue":"10","key":"e_1_2_1_94_2","first-page":"475","article-title":"The therapy of arterial hypertension: a comparison between ACE inhibitors and angiotensin II\u2010receptor antagonists","volume":"147","author":"Rossi F","year":"1996","journal-title":"Clin Ter"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960181507"},{"key":"e_1_2_1_96_2","first-page":"211","article-title":"Nonpeptide angiotensin II receptor antagonists XI. Pharmacology of EXP 3174: an active metabolite of DuP 753, an orally active antihypertensive agent","volume":"255","author":"Wong PC","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(97)82002-5"},{"issue":"2","key":"e_1_2_1_98_2","first-page":"281","article-title":"The metabolism of DuP753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices","volume":"20","author":"Stearns RA","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_99_2","volume-title":"Losartan potassium tablets. Prescribing information","author":"Cozaar\u00ae","year":"1997"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04146.x"},{"key":"e_1_2_1_101_2","first-page":"S7","article-title":"The advantages of angiotensin II antagonism","volume":"12","author":"Burnier M","year":"1994","journal-title":"J Hypertens"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050317"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb13877.x"},{"key":"e_1_2_1_104_2","volume-title":"Valsartan capsules","author":"Diovan\u00ae","year":"1997"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00391-9"},{"key":"e_1_2_1_106_2","first-page":"91","article-title":"In vitro N\u2010glucuronidation of SR 47436 (BMS 186295), a new AT1 non\u2010peptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions","volume":"271","author":"Perrier L","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_107_2","volume-title":"Irbesartan tablets","author":"Avapro\u00ae","year":"1997"},{"issue":"2","key":"e_1_2_1_108_2","first-page":"S9","article-title":"Candesartan cilexetil: a review of its preclinical pharmacology","volume":"11","author":"Nishikawa K","year":"1997","journal-title":"J Hum Hypertens"},{"issue":"2","key":"e_1_2_1_109_2","first-page":"S27","article-title":"Absorption, metabolism and excretion of 14C\u2010Candesartan and 14C\u2010Candesartan cilexetil in healthy volunteers","volume":"11","author":"Lier JJ","year":"1997","journal-title":"J Hum Hypertens"},{"key":"e_1_2_1_110_2","volume-title":"Candesartan cilexetil tablets","author":"Atacand\u00ae","year":"1998"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-199403000-00014"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1053\/hj.1998.v135.86971"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.65.4.869"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1998.274.3.H874"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007795915009"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00052506"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.31.1.487"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00208-3"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00210-1"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.14.1411"},{"issue":"3","key":"e_1_2_1_121_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0733-8651(18)30036-5","article-title":"Angiotensin\u2010converting enzyme inhibitors post myocardial infarction","volume":"13","author":"Young JB","year":"1995","journal-title":"Cardiol Clin"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000634"},{"key":"e_1_2_1_123_2","first-page":"509","article-title":"Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor\u2010B1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats","volume":"273","author":"Kim S","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"e_1_2_1_124_2","first-page":"H1824","article-title":"Dose\u2010dependent effect of ANG II\u2010receptor antagonist on myocyte remodeling in rat cardiac hypertrophy","volume":"273","author":"Obayashi M","year":"1997","journal-title":"Am J Physiol"},{"key":"e_1_2_1_125_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199506000-00015"},{"key":"e_1_2_1_126_2","first-page":"S137","article-title":"Comparison of irbesartan to captopril in heart failure prone male SHHF\/MCCFAcp rats","volume":"14","author":"McCune SA","year":"1996","journal-title":"J Hypertens"},{"issue":"6","key":"e_1_2_1_127_2","first-page":"H2468","article-title":"ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice","volume":"226","author":"Rockman HA","year":"1994","journal-title":"Am J Physiol"},{"key":"e_1_2_1_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00506-4"},{"issue":"5","key":"e_1_2_1_129_2","first-page":"625","article-title":"Pharmacological profile of valsartan, a non\u2010peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valsartan","volume":"46","author":"Hayashi N","year":"1997","journal-title":"Arzniemettelforschung"},{"key":"e_1_2_1_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(94)90002-7"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641969709083206"},{"key":"e_1_2_1_132_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.404"},{"key":"e_1_2_1_133_2","first-page":"195","article-title":"Role of angiotensin II in renal injury of deoxycorticosterone acetate\u2010salt hypertensive rats","volume":"24","author":"Wada T","year":"1995","journal-title":"Hypertens"},{"key":"e_1_2_1_134_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1998.274.1.F79"},{"key":"e_1_2_1_135_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1995.tb02955.x"},{"key":"e_1_2_1_136_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.246"},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.20"},{"key":"e_1_2_1_138_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.32.2.305"},{"key":"e_1_2_1_139_2","first-page":"16","article-title":"Angiotensin II antagonists: present applications and future prospects in cardiovascular disease","volume":"10","author":"Higginbotham MB","year":"1998","journal-title":"Contemp Internat Med"},{"key":"e_1_2_1_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01187-2"},{"key":"e_1_2_1_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00390-7"},{"key":"e_1_2_1_142_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199507001-00008"},{"key":"e_1_2_1_143_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.3.691"},{"key":"e_1_2_1_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(05)70585-X"},{"issue":"1","key":"e_1_2_1_145_2","first-page":"S12","article-title":"Angiotensin II type\u2010I receptor antagonists in the treatment of heart failure","volume":"62","author":"Nicholls GM","year":"1997","journal-title":"Int J Cardiol"},{"issue":"17","key":"e_1_2_1_146_2","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/archinte.1996.00440160069010","article-title":"Angiotensin II receptor inhibition: a new therapeutic principle","volume":"156","author":"Messerli FH","year":"1996","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_147_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/16.suppl_N.86"},{"key":"e_1_2_1_148_2","first-page":"467","article-title":"Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair","volume":"17","author":"Weber KT","year":"1997","journal-title":"Semin Nephrol"},{"issue":"1","key":"e_1_2_1_149_2","first-page":"25","article-title":"Contribution of kinins to the cardiovascular actions of angiotensin\u2010converting enzyme inhibitors","volume":"47","author":"Linz W","year":"1995","journal-title":"Pharmacol Rev"},{"issue":"2","key":"e_1_2_1_150_2","first-page":"S1","article-title":"Do we need angiotensin II antagonists to treat hypertensive patients?","volume":"11","author":"Menard J","year":"1997","journal-title":"J Hum Hypertens"},{"key":"e_1_2_1_151_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.30.6.1621"},{"key":"e_1_2_1_152_2","doi-asserted-by":"publisher","DOI":"10.1159\/000176945"},{"issue":"1","key":"e_1_2_1_153_2","first-page":"71","article-title":"Vascular renin\u2010angiotensin system, endothelial function and atherosclerosis?","volume":"89","author":"Holtz J","year":"1994","journal-title":"Basic Res Cardiol"},{"key":"e_1_2_1_154_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007739412802"},{"key":"e_1_2_1_155_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.29.2.634"},{"issue":"2","key":"e_1_2_1_156_2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1681\/ASN.V92224","article-title":"Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5\/6 renal mass ablation","volume":"9","author":"Ots M","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_1_157_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.29.1.519"},{"issue":"7","key":"e_1_2_1_158_2","first-page":"S380","article-title":"Phase I results of the randomized evaluation of left ventricular dysfunction (RESOLVD) trial","volume":"4","author":"Yusuf S","year":"1998","journal-title":"Am J Man Care"},{"key":"e_1_2_1_159_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199710000-00020"},{"key":"e_1_2_1_160_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03228-0"},{"key":"e_1_2_1_161_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.10.10.5536"},{"key":"e_1_2_1_162_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(96)00251-3"},{"key":"e_1_2_1_163_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(95)00063-1"},{"key":"e_1_2_1_164_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117243"},{"key":"e_1_2_1_165_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.2.442"},{"key":"e_1_2_1_166_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"issue":"12","key":"e_1_2_1_167_2","first-page":"1166","article-title":"Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta\u2010blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study","volume":"13","author":"Tsuyuki RT","year":"1997","journal-title":"Can J Cardiol"},{"key":"e_1_2_1_168_2","first-page":"133","article-title":"A randomized trial evaluating tolerability of candesartan cilexetil for patients with congestive heart failure and intolerance to angiotensin converting enzyme inhibitors (abstract)","volume":"19","author":"Granger C","year":"1998","journal-title":"Eur Heart J"},{"key":"e_1_2_1_169_2","first-page":"S140","article-title":"Angiotensin receptor antagonists in experimental models of chronic renal failure","volume":"63","author":"Mackenzie HS","year":"1997","journal-title":"Kidney Int"},{"key":"e_1_2_1_170_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1996.tb03076.x"},{"key":"e_1_2_1_171_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199812060-00001"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F00912709922008155","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/00912709922008155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T22:02:47Z","timestamp":1698530567000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/00912709922008155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,6]]},"references-count":170,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1999,6]]}},"alternative-id":["10.1177\/00912709922008155"],"URL":"https:\/\/doi.org\/10.1177\/00912709922008155","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,6]]}}}